• Dominion Aesthetic Technologies

  Participated · Series B · Feb 2021

  Dominion Aesthetic Technologies is a Houston-based medical device company advancing EON, an FDA-cleared 1064 nm robotic laser device for touchless, external non-invasive lipolysis of the abdomen. EON’s treatment head combines a laser that heats adipose tissue to induce apoptosis with a jet-inspired impingement cooling system to protect the skin and provide patient comfort. A microprocessor-controlled articulated robotic arm delivers consistent applications of laser energy over the designated treatment area. The company intends to use the Series B proceeds to accelerate manufacturing and commercialization of EON. The closing of the round followed Dominion’s relocation from San Antonio to its Houston headquarters, a site located within five minutes of Houston Bush Intercontinental Airport and inside a Qualified Opportunity Zone.

• Neurana Pharmaceuticals

  Participated · Series A · May 2018

  Neurana Pharmaceuticals is a San Diego-based specialty pharmaceutical company advancing tolperisone, a patented skeletal muscle relaxant for treatment of acute, painful muscle spasms and spasticity without sedation. Tolperisone is approved and used in Europe and Asia but has not been available in the U.S. due to an impurity that exceeded ICH guidelines. Neurana holds an exclusive license from Sanochemia AG to develop and commercialize a composition of tolperisone that meets ICH guidelines in North America. The company plans to commence a Phase 2 dose-ranging clinical trial later this year in subjects with acute, painful neuromuscular spasms of the neck and back. Led by David F. Hale as Chairman and Interim President & CEO, Neurana intends to use recently raised funds to further develop tolperisone. The company completed a $60M Series A financing to support those development efforts.

• Diamond Orthopedic

  Led · Seed · Nov 2017

  Diamond Orthopedic develops faceted threadform technology for orthopedic applications worldwide and has deployed that technology in an FDA-cleared faceted bone screw. The company holds exclusive rights to market and sell more than 2,500 FDA-cleared SKUs, including cortical, cancellous, headless compression, and external fixation screws. Led by CEO Roy Bivens, Diamond supplies a broad portfolio of orthopedic screw products. The business is based in Charlotte, N.C. Financially, the company completed a $3.5M seed funding round. The funding round was positioned to support the company's orthopedic product commercialization and distribution efforts.

• Forge Therapeutics

  Led · Series A · Apr 2017

  Forge Therapeutics is a San Diego-based biotechnology startup focused on developing antibiotics to treat lung infections. The company is working on antibiotic candidates aimed at respiratory infections. In January 2019 the company announced funding commitments totaling $11.1M from CARB-X. According to the announcement, Forge will initially receive $5.7M from CARB-X. CARB-X is described in the article as a public-private investor that funds projects targeting antibiotic-resistant bacteria. Forge Therapeutics discovers and develops small-molecule antibiotics that inhibit metalloenzymes in multi-drug resistant Gram-negative bacteria. Its proprietary chemistry approach is used to design inhibitors of zinc-dependent metalloenzymes, with a lead program against LpxC, an enzyme essential for Gram-negative bacterial growth. The company intends to advance its LpxC inhibitor into clinical studies. Forge is led by CEO Zachary A. Zimmerman, Ph.D. The company completed a financing to support near-term clinical advancement of its lead candidate. The business focuses on addressing the global health threat posed by so-called 'superbugs.'

No current team members are available.